Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Data on withdrawals due to lack of efficacy as reported in included RCTs

Trial name	First author	Treatment group	N withdrawing lack of efficacy
Adalimumab			
ULTRA1	Reinisch	PBO	Week 8, 4/130 (3.1%)
		ADA 160/80	Week 8, 1/130 (<1%)
ULTRA2	Sandborn	PBO	Week 52, 70/260 (26.9%)
		ADA 160/80	Week 52, 63/258 (24.2%)
Suzuki	Suzuki	PBO	Week 8, 2/96 (2.0%) Week 52, 14/96 (14.6%)
		ADA 80/40	Week 8, 1/87 (1.1%) Week 52, 17/87 (19.5%)
		ADA 160/80	Week 8, 1/90 (1.1%) Week 52, 16/90 (17.7%)
Golimumab			
PURSUIT-SC	Sandborn	PBO	NR
		GOL 200/100	NR
PURSUIT-M	Sandborn	PBO	NR
		GOL 200/100	NR
Infliximab			
ACT 1	Rutgeerts	PBO	NR
		IFX 5mg	NR
ACT 2	Rutgeerts	PBO	NR
		IFX 5mg	NR
UC-SUCCESS	Panaccionne	AZA	Week 16, 0/80 (0%)
		IFX	Week 16, 0/79 (0%)
		AZA/IFX	Week 16, 0/80 (0%)
Probert	Probert	PBO	Week6, 0/20 (0%)
		IFX 5mg	Week 6, 0/23 (0%)
Hyams (paediatric)	Hyams	IFX 5mg q8w	Week 54, 1/22 (4.5%)
		IFX 5mg q12w	Week 54, 4/23 (17.4%)